Atypical antipsychotics offer significant improvements over older, conventional antipsychotic
agents. However, recently the newer agents have been linked to medical morbidity including …

Recently, there has been increased concern about the occurrence of diabetes associated
with the use of atypical antipsychotic (AAP) drugs. The relationship between diabetes …

Recently, increasing attention has been drawn to the potential diabetogenic effect of novel
antipsychotics. Until now, large prospective studies examining the relationship between …

The link between atypical antipsychotic drugs and the development of diabetes has been
hotly debated in the literature. In this review, we attempt to classify the various types of data …

Aims Atypical anti‐psychotic drugs (APDs) are widely used in psychotic disorders refractory
to conventional neuroleptic agents. Results Three cases of new‐onset diabetes are reported …

BACKGROUND Since the introduction of atypical antipsychotic medications, beginning with
clozapine in 1990, several case reports in the psychiatric literature have suggested that they …

OBJECTIVE: The purpose of the study was to determine the proportion of patients with
schizophrenia with a stable regimen of antipsychotic monotherapy who developed diabetes …

Second-generation (atypical) antipsychotic medications are of great benefit to a wide variety
of people with psychiatric disorders, especially patients with schizophrenia. However, one …

As a class, the atypical antipsychotics are the first line treatment choice for the
psychopharmacologic management of psychotic disorders. Emerging evidence currently …

Background. Some atypical antipsychotics have been linked to hyperglycemia, diabetes
mellitus, and diabetic ketoacidosis. We reviewed evidence comparing excess risk and …